I-MAB SPONS.ADS/1 -0001 Market Cap ($144.67 Million)
Market Cap & Net Worth: I-MAB SPONS.ADS/1 -0001 (0VY)
I-MAB SPONS.ADS/1 -0001 market cap. I-MAB SPONS.ADS/1 -0001 (F:0VY) has a market capitalization of $144.67 Million (€123.74 Million) as of November 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #17600 globally and #1649 in its home market, demonstrating a -6.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying I-MAB SPONS.ADS/1 -0001's stock price €1.07 by its total outstanding shares 115648505 (115.65 Million). Also see 0VY cash flow metrics for how efficiently the company converts equity into cash flow.
I-MAB SPONS.ADS/1 -0001 Market Cap History (2020–2026)
I-MAB SPONS.ADS/1 -0001 market cap history from 2020 to 2026. Data shows change from $4.46 Billion to $144.67 Million (-30.37% CAGR). Check I-MAB SPONS.ADS/1 -0001 stock price for real-time trading data and today's change.
I-MAB SPONS.ADS/1 -0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how I-MAB SPONS.ADS/1 -0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore I-MAB SPONS.ADS/1 -0001 (0VY) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
352.99x
I-MAB SPONS.ADS/1 -0001's market cap is 352.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.44 Billion | $13.81 Million | -$365.78 Million | 393.58x | N/A |
| 2022 | $451.59 Million | $-1.55 Million | -$371.05 Million | -291.16x | N/A |
| 2023 | $223.09 Million | $632.00K | -$207.73 Million | 352.99x | N/A |
Competitor Companies of 0VY by Market Capitalization
Companies near I-MAB SPONS.ADS/1 -0001 in the global market cap rankings as of November 2, 2026. Also see I-MAB SPONS.ADS/1 -0001 total assets for a full breakdown of the balance sheet.
Key companies related to I-MAB SPONS.ADS/1 -0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of I-MAB SPONS.ADS/1 -0001 (2020–2026)
Market capitalization of I-MAB SPONS.ADS/1 -0001 from 2020 to today. Between 2020 and today, I-MAB SPONS.ADS/1 -0001's market cap moved from $4.46 Billion to $ 144.67 Million, with a yearly change of -30.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €144.67 Million | -67.96% |
| 2025 | €451.59 Million | +300.00% |
| 2024 | €112.90 Million | -49.39% |
| 2023 | €223.09 Million | -50.60% |
| 2022 | €451.59 Million | -91.69% |
| 2021 | €5.44 Billion | +21.82% |
| 2020 | €4.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of I-MAB SPONS.ADS/1 -0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $144.67 Million USD |
| MoneyControl | $144.67 Million USD |
| MarketWatch | $144.67 Million USD |
| marketcap.company | $144.67 Million USD |
| Reuters | $144.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more